Showing results (181-190 of 311) with videos related to

Sort By:
Pageof 32
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|April 1, 1985
High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary resultsM Bruzzone, P F Conte, S Chiara, et al.
American Journal of Clinical Oncology|August 24, 2000
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumorsS Ricci, A Antonuzzo, L Galli, et al.
British Journal of Cancer|May 20, 2004
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) groupA Buda, I Floriani, R Rossi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 1, 1991
Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancerS Chiara, M Orsatti, P Franzone, et al.
Seminars in Oncology|October 1, 1996
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patientsA Michelotti, A Gennari, B Salvadori, et al.
Gynecologic Oncology|June 12, 2003
First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patientsA Romanini, L Tanganelli, F Carnino, et al.
European Journal of Gynaecological Oncology|January 1, 1992
Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO)A Gadducci, I Brunetti, M Bruzzone, et al.
Cellular and Molecular Life Sciences : CMLS|April 25, 2007
How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?T Edouard, A Montagner, M Dance, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Thymidine labelling index as prognostic factor in resected non-small cell lung cancerA Alama, M Costantini, L Repetto, et al.
Oncology|January 1, 1987
Multimodality treatment of locally advanced breast cancerR Lionetto, P Pronzato, P F Conte, et al.
Pageof 32